Irene Feiner, PhD, is a postdoc at the LBI:AD. Her background relies on a biomedical chemistry study conducted at the Johannes Gutenberg Universität Mainz. She obtained her PhD in 2020 from EHU/UPV working at the research center CIC biomaGUNE in San Sebastián, Spain, with the project to develop a pretargeting approach for boron enriched nanoparticles with application in Boron Neutron Capture Therapy (BNCT).

Since the end of 2020 she joined the LBI:AD, where her research interests lie in using molecular imaging for drug development. Currently she is working on the development of novel hydroxamate chelators for various radiometals used in nuclear oncology (diagnostic and imaging).